News

Reproduction number should govern allocation of the shot, researchers say.

New polls shows confidence in AstraZeneca vaccine plummets in Europe.

The small country's emphasis on accessible testing provided more up-to-date tracking, and opportunity for research into reinfection risk.

After a year of setbacks, AZD1222 has been associated with 100% prevention of severe COVID-19 in US trial participants. Could emergency authorization come soon?

An interview on perspectives learned from a nationwide PCR test database assessment.

The Infectious Diseases Society of America (IDSA) discusses some of the new treatments show measurable impact on severe disease and death.

8% of ischemic stroke patients had atrial fibrillation, while 9% of those without stroke also had atrial fibrillation.

COVID-19 vaccine development demanded an adults-first approach. A year in, children are being invited to participate in trials in hopes of getting the pediatric population vaccinated later this year.

Machine learning is a promising and potentially powerful technique for detection and prognosis of disease.

Regardless of symptom status, the rate of participants positive for pan-immunoglobulins with neutralizing antibodies at baseline remained stable throughout 2020.

Approaches that measure the indirect effect of the virus on the host may offer complementary solutions in clinical or mass testing.

New drugs likely won’t meet resistance challenges ahead, authors say.

Getting kids back in classrooms is crucial, and it can be done with planning and forethought.

The US was poised in many ways to handle a public health emergency, but the attempt was largely a failure. What happened and how can we push forward?

No causative link has been established between the shot and blood clots or severe bleeding.

Ultrasound is known to cause the breaking up of kidney stones and opening the lipid shell of liposome for drug delivery.

Recruitment for a phase 2 trial of a novel antibiotic against Clostridium difficile (C diff) is proceeding after phase 1 demonstrated safety and tolerability.

The new findings support increased protection from reinfection up to 6 months after first testing positive, though older patients are at greater risk of reinfection.

Researchers and clinicians continually failed to connect with the greater public on matters of the pandemic. What drove the divide between the already distanced groups?

To minimalize mouth rinse-associated cytotoxicity, mouth rinse was largely removed from treated viruses by centrifugation prior to infection of cells.

Findings underscore the need to stay on top of emerging mutations through aggressive genomic surveillance.

New World Obesity Foundation report finds higher COVD-19 mortality rates in countries with higher prevalence of obesity.

A 2-dose vaccination regimen did not show protection against mild-to-moderate disease due to the B.1.351 variant.

CT imaging can detect illness in the lungs better than other medical imaging like MRI.

A Phase 2 study evaluating the therapy could begin immediately based on the findings.

The vaccine is currently authorized for use under an EUA in individuals 18 years of age and older.

Melinta Therapeutics’ oritavancin therapy is indicated for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult patients.

Adults with mild cases of COVID-19 did not fare better if they were treated with Ivermectin or placebo.

While most methods of sterilization are effective, efficacy can vary depending on the design of particular masks.

Number of cases surge in the pacific island nation of Papua New Guinea.